Chemosensitization of androgen-independent prostate cancer with neutral endopeptidase

We investigated whether neutral endopeptidase (NEP) could augment chemosensitivity to anticancer drugs by promoting protein kinase C (PKC)delta-mediated mitochondrial apoptosis in prostate cancer (PC) cells.

Human PC cell lines LNCaP and PC-3, and a normal prostate epithelial cell line (PrEC) were used. The protein expression was detected by Western blot analysis, and the protein turnover was determined by pulse-chase assay. Apoptotic ratio was measured by annexin V staining.

Western blot analyses and pulse-chase assays showed that the specific NEP inhibitor CGS24592 decreased PKCdelta protein expression by promoting PKCdelta protein degradation in NEP-expressing LNCaP cells. Conversely, recombinant NEP (rNEP) increased PKCdelta protein expression by delaying PKCdelta protein degradation in NEP-negative PC-3 cells. Apoptosis assays showed that rNEP promoted anticancer drug-induced apoptosis in PC-3 cells specifically through PKCdelta activity that mediated anticancer drug-induced mitochondrial change such as cytochrome-c release and caspase-9 activation. Of note, rNEP was able to increase PKCdelta protein expression predominantly in PC-3 cells rather than in PrEC cells. Treatment with rNEP before subtoxic concentrations of etoposide (0.1 micro M) significantly promoted mitochondrial apoptosis compared with only etoposide in PC-3 cells (P < 0.01) but not in PrEC cells.

These results suggest that NEP enzyme activity contributes to anticancer drug-induced PC cell apoptosis dependent on PKCdelta-mediated mitochondrial events. More importantly, the combination of NEP with anticancer drugs may be a promising therapeutic modality because rNEP is able to augment chemosensitivity in androgen-independent PC with minimal toxicity in normal tissues.